← All Market Monitors SANOR About SANOR

Novo Nordisk

Other 🇩🇰, Denmark

Novo Nordisk develops and manufactures medicines for diabetes and obesity, including Ozempic and Wegovy (semaglutide). Its GLP-1 business includes injectable and oral formulations. This profile follows its product launches, commercial expansion and financial updates as it competes for patients and market share.

www.novonordisk.com

Market Cap

$189.3bn

As of 2026-09-14 · USD · Recorded monthly observations

Ticker Mentions

4

Last 12 months

Deal Activity

0

Last 12 months

Deals · Novo Nordisk

No published records yet.

Free Playbook

The Private Clinic Playbook

Grow revenue at each location and build a commercial model that can scale across a clinic group.

Sanor never sells your personal information. By providing this information you agree to Sanor’s Privacy Policy and Terms of Service.

Privacy Policy Terms of Service Disclaimer Sitemap

SANOR research follows the principles of ISO 20252:2019 and the ICC/ESOMAR International Code on Market, Opinion and Social Research and Data Analytics, and is conducted in line with our Independence Policy. Our published reports follow our Editorial Standards.

SANOR research is funded through advisory engagements and research licensing. We do not accept vendor sponsorship, paid placement, or advertising.

All publications are provided for general information only. They do not constitute medical, financial, or investment advice and do not account for the circumstances of any specific business or individual.

© 2026 SANOR Intelligence